Psychedelic companies say Compass study result validates industry’s hope to find alternative treatments for mental health

Psychedelic companies feel that Compass Pathways results validate efforts to develop next-generation medicine for treating mental health issues

Compound MDMA
Visit article
Category Press Release
Country United Kingdom

Companies Featured

COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.